breast cancer Archives -

Market Access/ News/ News/ News/ Oncology

AZ gets FDA nod for Enhertu in first HER2-low cancer

Phil Taylor AstraZeneca, breast cancer, Enhertu, fda, her2, Oncology, regulatory approval 0 Comment

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for HER2-low breast cancer,

AZ gets FDA nod for Enhertu in first HER2-low cancer

https://pharmaphorum.com/news/az-gets-fda-nod-for-enhertu-in-first-her2-low-cancer/

Radiology technician examens mammography test

News/ News/ News/ Oncology/ Sales and Marketing

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

Phil Taylor adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology 0 Comment

The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant treatment for breast cancer,

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-eu-nod-for-lynparza-as-adjuvant-breast-cancer-therapy/

News/ News/ Oncology

FDA verdict on Enhertu in HER2-low breast cancer due before year-end

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, fda, her2, Oncology 0 Comment

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license

FDA verdict on Enhertu in HER2-low breast cancer due before year-end

https://pharmaphorum.com/news/fda-verdict-on-enhertu-in-her2-low-breast-cancer-due-before-year-end/

Market Access/ News/ News/ News/ Oncology

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa 0 Comment

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

https://pharmaphorum.com/news/az-daiichi-challenge-roche-with-eu-okay-for-earlier-use-of-enhertu/

Market Access/ News/ News/ News/ Oncology

Byondis cues up US, EU decisions on breast cancer ADC in 2023

Phil Taylor AstraZeneca, breast cancer, Byondis, Daiichi Sankyo, Enhertu, her2, Kadcyla, Oncology, Roche 0 Comment

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible

Byondis cues up US, EU decisions on breast cancer ADC in 2023

https://pharmaphorum.com/news/byondis-cues-up-us-eu-decisions-on-breast-cancer-adc-in-2023/

Market Access/ News/ News/ News/ Oncology

NICE backs two new breast cancer drugs for NHS use

Phil Taylor breast cancer, Gilead Sciences, HEOR, NHS, NICE, Novartis, Oncology, Piqray, Trodelvy 0 Comment

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer

NICE backs two new breast cancer drugs for NHS use

https://pharmaphorum.com/news/nice-backs-two-new-breast-cancer-drugs-for-nhs-use/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

Phil Taylor breast cancer, Eli Lilly, HEOR, NHS, NICE, Oncology, Verzenio 0 Comment

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

https://pharmaphorum.com/news/lillys-verzenios-gets-nice-blessing-for-early-stage-breast-cancer/

Digital/ News/ News

Lilly partners with Sidekick in digital health alliance

Phil Taylor breast cancer, digital, digital health, digital therapeutics, Eli Lilly, Oncology, partnering, Sidekick Health 0 Comment

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from

Lilly partners with Sidekick in digital health alliance

https://pharmaphorum.com/news/lilly-partners-with-sidekick-in-digital-health-alliance/

Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

Redefining the approach to cancer care – a mission to improve patient outcomes

mike.hammerton@pharmaphorum.com breast cancer, cancer care, company profile, Exact Sciences, her2 0 Comment

Each year across Europe, 3.7 million people are diagnosed with a form of cancer, resulting in 1.9 million

Redefining the approach to cancer care – a mission to improve patient outcomes

https://pharmaphorum.com/oncology/redefining-the-approach-to-cancer-care-a-mission-to-improve-patient-outcomes/

Trending

breast cancer

Login